

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

GENEDX, INC.  
Petitioner

v.

MYRIAD GENETICS, INC.  
Patent Owner

U.S. Patent No. 6,051,379

---

*Inter Partes* Review Case No. Unassigned

---

**DECLARATION OF MADHURI HEGDE, PH.D, FACMG**

## TABLE OF CONTENTS

I.	Introduction.....	1
II.	My Background and Qualifications.....	2
III.	List of Documents I Considered in Formulating My Opinions .....	4
IV.	Person of Ordinary Skill in the Art.....	6
V.	The ‘379 Patent Specification.....	8
VI.	Overview of the Challenged Claims of the ‘379 patent .....	9
VII.	Claim Construction .....	11
VIII.	State of the Art as of September 23, 1997.....	13
IX.	Summary Chart of Analysis Over the Art .....	26
X.	The Basis of my Analysis with Respect to Obviousness .....	27
XI.	Ground 1: Tavigian in view of Shattuck-Eidens provide a reason to arrive at the invention of Claims 7, 8, 13, 14, 16, 17, 19, 20, 32, and 33 with a reasonable expectation of success .....	28
XII.	Ground 2: Wooster in view of Shattuck-Eidens provide a reason to arrive at the invention of claims 7, 8, 13, 14, 16, 17, 19, 20, 32, and 33 with a reasonable expectation of success .....	65

XIII. Objective Indicia of Nonobviousness..... 99

XIV. Conclusion ..... 105

I, Madhuri Hegde, Ph.D, FACMG, hereby declare as follows.

***I. Introduction***

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

2. I have been retained as an expert witness on behalf of GENEDX, INC., (“GENEDX”) for the above-captioned *inter partes* review (IPR). I am being compensated for my time in connection with this IPR at my standard legal consulting rate, which is \$350 per hour. I understand that the petition for *inter partes* review involves U.S. Patent No. 6,051,379 (“the ‘379 patent”), GDX1001, which resulted from U.S. Application No. 08/984,034 (“the ‘034 application”). I understand that the ‘379 patent claims priority to U.S. Patent Application No. 60/059,595, filed September 23, 1997. The ‘379 patent names Jennifer Lee Lescallett, Tammy Lawrence, Antonette Preisinger Allen, Sheri Jon Olson, Denise Bernadette Thurber, and Marga Belle White as inventors. The ‘379 patent issued on April 18, 2000 from the ‘034 application. I understand that, according to the USPTO records, the ‘379 patent is currently assigned to Myriad Genetics, Inc. (“the patentee”).

3. In preparing this Declaration, I have reviewed the ‘379 patent and each of the documents cited herein, in light of general knowledge in the art. In formulating my opinions, I have relied upon my experience, education and

knowledge in the relevant art. In formulating my opinions, I have also considered the viewpoint of a person of ordinary skill in the art (“POSA”) (*i.e.*, a person of ordinary skill in the field of genetics, defined further below in Section IV) prior to September 23, 1997.

## *II. My Background and Qualifications*

4. I am an expert in the field of recombinant DNA technology, medical genetics, and genetic diagnostics. I received my B.S. and M.Sc. in Microbiology/Genetics from the University of Bombay, Bombay, India in 1987 and 1992, respectively. I was a Senior Research Fellow at University Hospital, University of Bombay, Bombay, India in 1992-1995 and Scientific Officer at DNA Diagnostic Laboratory, Auckland Hospital, Auckland, New Zealand in 1995-1996. I received my Ph.D. in Applied Science, with thesis titled "Molecular – Based Diagnostics of Inherited Disorders: Multiple Exon and Trinucleotide Repeat Expansion Analysis," from the University of Auckland, Auckland, New Zealand in 2000, and I was a Postdoctoral Fellow in Clinical Molecular Genetics at the Department of Human Genetics at Baylor College of Medicine, Houston, Texas in 2000-2003.

5. I became an Assistant Professor in the Department of Human Genetics at Baylor College of Medicine, Houston, Texas in 2003, and then an Assistant Professor in the Department of Human Genetics, Emory University School of

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.